Regulatory · Reviewed 2026-06-04

Semaglutide Shortage Status

Is semaglutide still in shortage? The short answer is no — and that status is exactly why compounding rules tightened.

Quick Answer

The FDA resolved the semaglutide shortage in February 2025. Because much compounding during 2022–2024 relied on shortage-list status, resolving the shortage removed that basis, and the FDA's 2026 proposal would further close the 503B bulks-list pathway.

Key Facts

Semaglutide is not currently on the FDA drug shortage list; it was removed in 2025.
Shortage-list status historically allowed broader compounding; its removal narrowed that allowance.
503A patient-specific compounding does not depend on shortage status.
Liraglutide injection has reportedly remained on the shortage list separately — verify current status per product.

Why it matters for price: providers that built around shortage-era compounding have had to adapt their pharmacy networks. Confirm how any current program sources its product. See the 2026 update.

What to Verify

Current shortage-list status on the FDA database before relying on any compounded supply claim.
Whether a provider's pathway is 503A or 503B.
Any provider promise of guaranteed supply (a red flag given the shifting rules).

Bottom Line

Semaglutide is no longer in shortage, which is the root cause of the tighter compounding environment. Verify product-level status directly with the FDA.

Compounded semaglutide is not FDA-approved as a finished drug product. Compounded medications may be prescribed only when clinically appropriate and must be evaluated by a licensed prescriber. Branded medications such as Wegovy and Ozempic are FDA-approved products; compounded semaglutide is different and should not be described as FDA-approved, “generic Wegovy,” or “generic Ozempic.”